EFFECTS OF SEMAGLUTIDE AND TIRZEPATIDE ON SKELETAL MUSCLE MASS AND SARCOPENIA RISK IN ADULTS WITH OBESITY OR OVERWEIGHT: A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6230Keywords:
GLP-1 Receptor Agonists, GLP-1/GIP Receptor Agonists, Sarcopenic Obesity, Lean Body MassAbstract
Background: GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists are highly effective therapies for obesity management. However, associated reductions in lean body mass have raised concerns regarding sarcopenia risk. This review evaluated whether these changes translate into clinically relevant sarcopenia or sarcopenic obesity.
Methods: A narrative review of the PubMed, Cochrane Library and Google Scholar databases was conducted up to May 2026, to evaluate GLP-1 receptor agonist effects on muscle mass, body composition, and sarcopenia-related outcomes.
Results: GLP-1 RAs produced substantial weight loss, with lean mass accounting for approximately 20–33% of total weight reduction, a proportion comparable to that reported with lifestyle and surgical interventions. Most studies reported preserved or improved muscle function despite reductions in lean mass. MRI studies demonstrated reduced intramuscular fat with only modest decreases in muscle volume. However, one retrospective study in older adults with type 2 diabetes reported concurrent declines in muscle mass and function, suggesting increased vulnerability in high-risk populations.
Conclusions: Current evidence does not support a uniformly increased risk of sarcopenia or sarcopenic obesity during GLP-1 RA therapy. Lean mass loss appears largely proportional to overall weight reduction and is generally not accompanied by clinically meaningful declines in muscle function. Older adults and individuals with low baseline muscle reserve may require closer monitoring.
References
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022b). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes Obesity and Metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
Caturano, A., Amaro, A., Berra, C. C., & Conte, C. (2025). Sarcopenic obesity and weight loss-induced muscle mass loss. Current Opinion in Clinical Nutrition & Metabolic Care, 28(4), 339–350. https://doi.org/10.1097/mco.0000000000001131
Voulgaridou, G., Tyrovolas, S., Detopoulou, P., Tsoumana, D., Drakaki, M., Apostolou, T., Chatziprodromidou, I. P., Papandreou, D., Giaginis, C., & Papadopoulou, S. K. (2024b). Diagnostic criteria and measurement techniques of sarcopenia: A critical evaluation of the up-to-date evidence. Nutrients, 16(3), 436. https://doi.org/10.3390/nu16030436
Cruz-Jentoft, A. J., & Sayer, A. A. (2019). Sarcopenia. The Lancet, 393(10191), 2636–2646. https://doi.org/10.1016/s0140-6736(19)31138-9
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024). Sarcopenic obesity in older adults: A clinical overview. Nature Reviews Endocrinology, 20(5), 261–277. https://doi.org/10.1038/s41574-023-00943-z
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., Rapp, C., Petit, A., Godin, M., Vignal, L., Grigioni, S., Déchelotte, P., Colange, G., Coëffier, M., & Achamrah, N. (2025). Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obesity and Metabolism, 28(1), 112–121. https://doi.org/10.1111/dom.70141
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2024c). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 164, 156113. https://doi.org/10.1016/j.metabol.2024.156113
Sattar, N., Neeland, I. J., Leinhard, O. D., Landó, L. F., Bray, R., Linge, J., & Rodriguez, A. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): A post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology, 13(6), 482–493. https://doi.org/10.1016/s2213-8587(25)00027-0
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Papanas, N. (2025). GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review. Diabetes Research and Clinical Practice, 229, 112924. https://doi.org/10.1016/j.diabres.2025.112924
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024). Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss? Circulation, 150(16), 1288–1298. https://doi.org/10.1161/circulationaha.124.067676
Ren, Q., Zhi, L., & Liu, H. (2025b). Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: A 24-month retrospective cohort study. Drug Design Development and Therapy, 19, 5645–5652. https://doi.org/10.2147/dddt.s531778
Rossi, G., Bucciarelli, L., Mananguite, C., Giovarelli, M., & Fiorina, P. (2025). Muscle loss and GLP-1R agonists use. Acta Diabetologica, 63(2), 333–342. https://doi.org/10.1007/s00592-025-02611-2
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021b). The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: Current evidence and underlying mechanisms. Cells, 10(8), 1958. https://doi.org/10.3390/cells10081958
Chrysavgis, L., Mourelatou, N. G., Koloutsou, M., Rozani, S., & Cholongitas, E. (2025b). The influence of glucagon-like peptide-1 receptor agonists and other incretin hormone agonists on body composition. International Journal of Molecular Sciences, 26(24), 12130. https://doi.org/10.3390/ijms262412130
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022b). GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1869(9), 119300. https://doi.org/10.1016/j.bbamcr.2022.119300
Min, T., & Bain, S. C. (2020b). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy, 12(1), 143–157. https://doi.org/10.1007/s13300-020-00981-0
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., Avihingsanon, A., Sattler, F. R., & Erlandson, K. M. (2024c). Effects of semaglutide on muscle structure and function in the SLIM LIVER study. Clinical Infectious Diseases, 80(2), 389–396. https://doi.org/10.1093/cid/ciae384
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025b). Nutritional priorities to support GLP‐1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 33(8), 1475–1503. https://doi.org/10.1002/oby.24336
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025c). Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacological Research, 220, 107927. https://doi.org/10.1016/j.phrs.2025.107927
Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y., Lv, F., Yang, W., & Ji, L. (2024b). Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis. Diabetes Obesity and Metabolism, 27(1), 259–267. https://doi.org/10.1111/dom.16012
Ramos, R. A. H., Hong, I., Ortiz, M., Secades, D., Krieger, S. D., & Stanziola, L. R. (2025b). Effects of tirzepatide on skeletal muscle mass in adults: A systematic review. Cureus, 17(7), e89020. https://doi.org/10.7759/cureus.89020
Bujdei-Tebeică, I., Mihai, D. A., Pantea-Stoian, A. M., Ștefan, S. D., Stoicescu, C., & Serafinceanu, C. (2025b). Effects of blood-glucose lowering therapies on body composition and muscle outcomes in type 2 diabetes: A narrative review. Medicina, 61(8), 1399. https://doi.org/10.3390/medicina61081399
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R. (2025b). Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia. Current Nutrition Reports, 14(1), 63. https://doi.org/10.1007/s13668-025-00649-w
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Szymon Mokrzecki, Anna Mamach , Ewa Bełc , Karolina Brzezińska , Katarzyna Aleksandrowicz , Zofia Grodzka, Mateusz Meszka , Matylda Król , Aleksandra Straszewska, Aleksandra Woźniak , Patrycja Sobantka , Mateusz Michał Pysiewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
